officialtpss | Recce https://www.recce.com.au Recce Wed, 25 Sep 2024 00:29:06 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://www.recce.com.au/wp-content/uploads/2023/09/cropped-cropped-favicon-32x32.png officialtpss | Recce https://www.recce.com.au 32 32 Recce Pharmaceuticals (ASX:RCE) receives green light for higher dose in rapid infusion phase I/II UTI trial https://www.recce.com.au/recce-pharmaceuticals-asxrce-receives-green-light-for-higher-dose-in-rapid-infusion-phase-i-ii-uti-trial/ https://www.recce.com.au/recce-pharmaceuticals-asxrce-receives-green-light-for-higher-dose-in-rapid-infusion-phase-i-ii-uti-trial/#respond Mon, 28 Aug 2023 17:02:55 +0000 https://demos.techpss.com/recce/?p=7006 https://www.recce.com.au/recce-pharmaceuticals-asxrce-receives-green-light-for-higher-dose-in-rapid-infusion-phase-i-ii-uti-trial/feed/ 0 Recce Pharmaceuticals — R327 progressing in rapid infusion study https://www.recce.com.au/recce-pharmaceuticals-r327-progressing-in-rapid-infusion-study/ https://www.recce.com.au/recce-pharmaceuticals-r327-progressing-in-rapid-infusion-study/#respond Thu, 24 Aug 2023 17:02:06 +0000 https://demos.techpss.com/recce/?p=7003 https://www.recce.com.au/recce-pharmaceuticals-r327-progressing-in-rapid-infusion-study/feed/ 0 Recce Pharmaceuticals (ASX:RCE) doses phase I/II patients in R327 diabetic foot infection trial https://www.recce.com.au/recce-pharmaceuticals-asxrce-doses-phase-i-ii-patients-in-r327-diabetic-foot-infection-trial/ https://www.recce.com.au/recce-pharmaceuticals-asxrce-doses-phase-i-ii-patients-in-r327-diabetic-foot-infection-trial/#respond Tue, 22 Aug 2023 16:59:21 +0000 https://demos.techpss.com/recce/?p=6999 https://www.recce.com.au/recce-pharmaceuticals-asxrce-doses-phase-i-ii-patients-in-r327-diabetic-foot-infection-trial/feed/ 0 Recce Pharmaceuticals (ASX:RCE) concludes stage one analysis of phase I/II R327 topical trial for burn wounds https://www.recce.com.au/recce-pharmaceuticals-asxrce-concludes-stage-one-analysis-of-phase-i-ii-r327-topical-trial-for-burn-wounds/ https://www.recce.com.au/recce-pharmaceuticals-asxrce-concludes-stage-one-analysis-of-phase-i-ii-r327-topical-trial-for-burn-wounds/#respond Mon, 21 Aug 2023 16:58:19 +0000 https://demos.techpss.com/recce/?p=6996 https://www.recce.com.au/recce-pharmaceuticals-asxrce-concludes-stage-one-analysis-of-phase-i-ii-r327-topical-trial-for-burn-wounds/feed/ 0 Recce Pharmaceuticals’ (ASX:RCE) new R327G shows positive response in treatment of antibiotic-resistant infections https://www.recce.com.au/recce-pharmaceuticals-asxrce-new-r327g-shows-positive-response-in-treatment-of-antibiotic-resistant-infections/ https://www.recce.com.au/recce-pharmaceuticals-asxrce-new-r327g-shows-positive-response-in-treatment-of-antibiotic-resistant-infections/#respond Tue, 08 Aug 2023 16:57:39 +0000 https://demos.techpss.com/recce/?p=6993 https://www.recce.com.au/recce-pharmaceuticals-asxrce-new-r327g-shows-positive-response-in-treatment-of-antibiotic-resistant-infections/feed/ 0 Recce Pharmaceuticals awarded Australian patent for lead anti-infectives https://www.recce.com.au/recce-pharmaceuticals-awarded-australian-patent-for-lead-anti-infectives/ https://www.recce.com.au/recce-pharmaceuticals-awarded-australian-patent-for-lead-anti-infectives/#respond Fri, 04 Aug 2023 16:57:04 +0000 https://demos.techpss.com/recce/?p=6990 https://www.recce.com.au/recce-pharmaceuticals-awarded-australian-patent-for-lead-anti-infectives/feed/ 0 Recce Pharmaceuticals (ASX:RCE) charges on with phase I/II UTI trial ahead of schedule https://www.recce.com.au/recce-pharmaceuticals-asxrce-charges-on-with-phase-i-ii-uti-trial-ahead-of-schedule/ https://www.recce.com.au/recce-pharmaceuticals-asxrce-charges-on-with-phase-i-ii-uti-trial-ahead-of-schedule/#respond Mon, 24 Jul 2023 16:56:30 +0000 https://demos.techpss.com/recce/?p=6987 https://www.recce.com.au/recce-pharmaceuticals-asxrce-charges-on-with-phase-i-ii-uti-trial-ahead-of-schedule/feed/ 0 Recce Pharmaceuticals (ASX:RCE) reports “positive” results from phase one R327 clinical trial https://www.recce.com.au/recce-pharmaceuticals-asxrce-reports-positive-results-from-phase-one-r327-clinical-trial/ https://www.recce.com.au/recce-pharmaceuticals-asxrce-reports-positive-results-from-phase-one-r327-clinical-trial/#respond Wed, 19 Jul 2023 16:55:56 +0000 https://demos.techpss.com/recce/?p=6984 https://www.recce.com.au/recce-pharmaceuticals-asxrce-reports-positive-results-from-phase-one-r327-clinical-trial/feed/ 0 Recce Pharmaceuticals verifies positive Phase 1 data from R327 intravenous study https://www.recce.com.au/recce-pharmaceuticals-verifies-positive-phase-1-data-from-r327-intravenous-study/ https://www.recce.com.au/recce-pharmaceuticals-verifies-positive-phase-1-data-from-r327-intravenous-study/#respond Wed, 19 Jul 2023 16:54:57 +0000 https://demos.techpss.com/recce/?p=6981 https://www.recce.com.au/recce-pharmaceuticals-verifies-positive-phase-1-data-from-r327-intravenous-study/feed/ 0 Recce Pharmaceuticals receives A$801,604 in R&D rebate advance https://www.recce.com.au/recce-pharmaceuticals-receives-a801604-in-rd-rebate-advance/ https://www.recce.com.au/recce-pharmaceuticals-receives-a801604-in-rd-rebate-advance/#respond Wed, 12 Jul 2023 16:54:13 +0000 https://demos.techpss.com/recce/?p=6978 https://www.recce.com.au/recce-pharmaceuticals-receives-a801604-in-rd-rebate-advance/feed/ 0